ライトストラテジーの適時開示・決算・その他

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): May 13, 2025

    

MEI Pharma, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-41827	51-0407811
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9920 Pacific Heights Blvd., Suite 150
San Diego, California		92121
(Address of principal executive Offices)		(Zip Code)

     Registrant’s telephone number, including area code: 858 369-7100

    

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00000002 par value	MEIP	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 13, 2025, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended March 31, 2025. The text of the press release is included as an exhibit to this Current Report on Form 8-K. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.



Exhibit No.		Description

99.1		Press Release issued by MEI Pharma, Inc., dated May 13, 2025.

104		Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the XBRL document.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			MEI PHARMA, INC.

Date:	May 13, 2025	By:	/s/ Justin J. File
			Acting Chief Executive Officer, Chief Financial Officer and Secretary

EX-99.1 2 meip-ex99_1.htm EX-99.1 EX-99.1

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

Evaluation of Strategic Alternatives is Ongoing

SAN DIEGO--(BUSINESS WIRE) — May 13, 2025 – MEI Pharma, Inc. (Nasdaq: MEIP) (the “Company”) today reported results for its third quarter ended March 31, 2025.

As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company is considering options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company’s exclusive financial advisor in this process.

Through the third quarter of fiscal year 2025, the Company’s cash preservation efforts continue and include a reduction-in-force progressing in stages as the Company’s operational and strategic direction evolves.

There can be no assurance the exploration of strategic alternatives will result in any agreements or transactions, or, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not expect to disclose developments with respect to this process unless or until the evaluation of strategic alternatives has been completed or the Board of Directors has concluded disclosure is appropriate or legally required.

As of March 31, 2025, the Company had $20.5 million in cash and cash equivalents with no outstanding debt.

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a pharmaceutical company with a portfolio of several drug candidates that may offer novel and differentiated cancer therapies. The drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor. For more information, please visit www.meipharma.com. Follow us on X (formerly Twitter) @MEI_Pharma and on LinkedIn.

Forward-Looking Statements

Certain information contained in this press release that are not historical in nature are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 including, without limitation, statements regarding the Company’s ability to identify, assess and execute a strategic transaction or realize value from its existing assets, the Company’s ability to preserve cash in order to adequately fund an orderly wind down of its operations if no transaction is consummated, the ability of stockholders and other stakeholders to realize any value or recovery as part of a transaction or a wind down process, the Company’s workforce reduction and future charges expected to be incurred in connection therewith, the adequacy or sufficiency of the Company’s existing cash resources and other statements. You should be aware that our actual results could differ materially from those

contained in the forward-looking statements, which are based on management’s current expectations and are subject to a number of risks and uncertainties, including, but not limited to, the Company’s ability to identify attractive strategic alternatives; the Company’s ability to retain key personnel; the adequacy of the Company’s capital resources in light of changing circumstances; the actions of various stakeholders of the Company; uncertainty regarding the impact of rising inflation, interest rates and tariffs; a potential economic downturn; activist investors; government regulation; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.

Contact:

Justin J. File

858-898-0976

investor@meipharma.com


	March 31, 2025			June 30, 2024
	(Unaudited)			(Audited)
ASSETS
Current assets:
Cash and cash equivalents	$	20,472		$	3,705
Short-term investments		—			34,640
Prepaid expenses and other current assets		307			2,424
Total current assets		20,779			40,769
Operating lease right-of-use asset		—			214
Property and equipment, net		—			392
Total assets	$	20,779		$	41,375
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	177		$	3,168
Accrued liabilities		1,061			5,187
Total current liabilities		1,238			8,355
Total liabilities		1,238			8,355
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.01 par value; 100 shares authorized; none outstanding		—			—
Common stock, $0.00000002 par value; 226,000 shares authorized; 6,663 shares issued and outstanding at March 31, 2025 and June 30, 2024		—			—
Additional paid-in capital		421,017			421,239
Accumulated deficit		(401,476	)		(388,219	)
Total stockholders’ equity		19,541			33,020
Total liabilities and stockholders’ equity	$	20,779		$	41,375


	Three Months Ended March 31,						Nine Months Ended March 31,
	2025			2024			2025			2024
Total revenues	$	—		$	—		$	—		$	65,297
Operating expenses:
Research and development		369			5,220			3,840			12,617
General and administrative		2,405			4,609			10,737			19,158
Total operating expenses		2,774			9,829			14,577			31,775
(Loss) income from operations		(2,774	)		(9,829	)		(14,577	)		33,522
Other income (expense):
Interest and dividend income		202			706			836			2,669
Gain on disposition of a non-financial asset		—			—			500			—
Other expense, net		(1	)		(4	)		(16	)		(7	)
Net (loss) income	$	(2,573	)	$	(9,127	)	$	(13,257	)	$	36,184

Net (loss) income per share - basic and diluted	$	(0.39	)	$	(1.37	)	$	(1.99	)	$	5.43
Weighted-average shares used in computing net (loss) income per share - basic and diluted:		6,663			6,663			6,663			6,663